J
Jean-Jacques Grob
Researcher at Aix-Marseille University
Publications - 369
Citations - 58038
Jean-Jacques Grob is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 71, co-authored 310 publications receiving 45788 citations. Previous affiliations of Jean-Jacques Grob include University of Sydney.
Papers
More filters
Journal ArticleDOI
Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.
Reinhard Dummer,Nicole Basset-Seguin,Johan Hansson,Jean-Jacques Grob,Rainer Kunstfeld,Brigitte Dréno,Laurent Mortier,Paolo A. Ascierto,Lisa Licitra,Caroline Dutriaux,Thomas Jouary,Nicolas Meyer,Bernard Guillot,Kate Fife,D. Scott Ernst,Sarah Williams,Alberto Fittipaldo,Ioannis Xynos,Axel Hauschild +18 more
TL;DR: An exploratory analysis is presented assessing the safety and efficacy profile in patients with treatment breaks in the STEVIE study focusing on safety of VISMO in pts with aBCC.
Journal ArticleDOI
Evidence of a Limited Intra-Individual Diversity of Nevi: Intuitive Perception of Dominant Clusters Is a Crucial Step in the Analysis of Nevi by Dermatologists
Yanal Wazaefi,Caroline Gaudy-Marqueste,M.-F. Avril,Joseph Malvehy,Giovanni Pellacani,Luc Thomas,Raoul Triller,Y. Bruneu,Sandrine Monestier,Marie-Aleth Richard,Bernard Fertil,Jean-Jacques Grob +11 more
TL;DR: The intra-individual diversity of nevi was studied using human ability to build "perceived similarity clusters" (PSCs) and found that inter-expert concordance permits a consensus representation of nevus diversity in each individual.
Journal ArticleDOI
Unfading acral microlivedo: A discrete marker of thrombotic skin disease associated with antiphospholipid antibody syndrome
Jean-Jacques Grob,M. San Marco,Marie-Françoise Aillaud,Lucille Andrac,B. Gabriel,Irène Juhan-Vague,C. Mercier,Jean-Jacques Bonerandi +7 more
TL;DR: Small erythematous or cyanotic lesions on the hands and feet of four patients with antiphospholipid antibodies are described, indicating antiph phosphate antibodies in apparently healthy patients, and could be a marker of risk for large-vessel thrombosis.
Journal ArticleDOI
Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.
Eve Maubec,Marouane Boubaya,Peter Petrow,Nicole Basset-Seguin,Jean-Jacques Grob,Brigitte Dréno,Marie Beylot-Barry,Isabelle Scheer-Senyarich,Sabine Helfen,Marie Thérèse Leccia,A. Stefan,Philippe Saiag,Julie De Quatrebarbes,Nicolas Meyer,Lydia Deschamps,Céline Alloux,Isabelle Lopez,Soufian Cherbal,Annick Tibi,Vincent Levy +19 more
TL;DR: The results of the CARSKIN study evaluating pembrolizumab in the first-line setting evaluating cSCCs with PD-1-axis blocking agent show encouraging results.
Journal Article
White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma.
TL;DR: Gender, age, Breslow thickness, and baseline WBC count, given an alphaIFN-WBC interaction, were independent predictors of DFI and may help to identify patients who are most likely to benefit fromalphaIFN.